Past studies have found secondary cytoreductive surgery (SCS) could significantly prolong time to progression both in isolated platinum-sensitive or resistant recurrent ovarian cancer patients, and BRCA1/2 status could also serve as an effective biomarker to select patients who may benefit from SCS, indicating by the significant improve in the progression-free survival than the wildtype patients (36, 37). This evidence concerns the gene BRCA1 and ovarian carcinoma.